XSHE
002773
Market cap2.80bUSD
Oct 09, Last price
20.66CNY
1D
1.52%
1Q
-7.40%
Jan 2017
-52.71%
IPO
86.77%
Name
Chengdu Kanghong Pharmaceutical Group Co Ltd
Chart & performance
P/E
16.37
P/S
4.15
EPS
1.26
Div yield, %
2.95%
Shrs. gr., 5y
0.08%
Rev. gr., 5y
6.83%
Revenues
4.59b
+2.98%
Net income
1.16b
-2.37%
CFO
1.50b
+6.50%
Dividend
Jun 09, 20260.7 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Chengdu Kanghong Pharmaceuticals Group Co., Ltd operates within China, focusing on the research, development, production, and marketing of a wide array of pharmaceutical goods. These include biologics, traditional Chinese medicines, and chemical drugs. The company's offerings span treatments for ophthalmic ailments, central nervous system conditions, digestive disorders, and other therapeutic areas. Founded in 1996, its corporate headquarters are located in Chengdu, China.
Key people
Zunhong Ke
Chairman of the Board · since 1998
Xiao Ke
President, Director · since 2019
Jianjun Zhong
Chief Financial Officer, Vice President · since 2023
Yanhua Xu
Executive Vice President · since 2023
Jinqun Yin
Vice President, Staff Elected Director · since 2025
Kang Deng
Secretary of the Board · since 2023
Lin Wang
Director · since 2011
Zhirong Zhang
Director · since 2023
Jianrong Zhong
Vice President, Director · since 2008
Hongguang Deng
Independent Director · since 2023
Nan Xu
Independent Director · since 2023
Demin Zhou
Independent Director · since 2023
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||